Nektar Therapeutics (NKTR) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $86.88: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.38; Below-average business quality. (Note: Risk dimension 3.0/10 and A.R:R 3.0:1 are different metrics that happen to read the same number here.)
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including rezpegaldesleukin (autoimmune), NKTR-255 (oncology), and NKTR-0165. The company has no commercial product revenue and is funded primarily through equity sales... Read more
Sell if holding. Engine safety override at $86.88: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.38; Below-average business quality. (Note: Risk dimension 3.0/10 and A.R:R 3.0:1 are different metrics that happen to read the same number here.) Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 4.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductrezpegaldesleukin10-K Item 1A: 'We are highly dependent on the success of drug candidates, particularly rezpegaldesleukin (previously referred to as NKTR-358).'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Revenue shrinking — -25.3% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -297.1%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $86.88: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.38; Below-average business quality. (Note: Risk dimension 3.0/10 and A.R:R 3.0:1 are different metrics that happen to read the same number here.) Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $80.86. Score 4.3/10, moderate confidence.
Take-profit target: $125.50 (+44.3% upside). Prior stop was $80.86. Stop-loss: $80.86.
Concentration risk — Product: rezpegaldesleukin; Quality below floor (3.7 < 4.0); Value-trap signals (2/5): Margin compression (op margin -3.4%), Material insider selling (104 sells, 0.26% of cap).
Nektar Therapeutics trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover NKTR with a consensus score of 4.3/5. Average price target: $144.
What does Nektar Therapeutics do?Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including...
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on immunotherapy, with a pipeline including rezpegaldesleukin (autoimmune), NKTR-255 (oncology), and NKTR-0165. The company has no commercial product revenue and is funded primarily through equity sales and collaboration agreements.